Variety of suitable individuals: CDEC talked about the uncertainty in the quantity of people with reasonably intense to severe hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some people that are classified as getting mild